Epacadostat plus pembrolizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037
O Hamid, TF Gajewski, AE Frankel… - Annals of …, 2017 - annalsofoncology.org
Background: Tumors can evade immunosurveillance through upregulation of indoleamine 2,
3-dioxygenase 1 (IDO1). Epacadostat (E) is a potent, selective inhibitor of the IDO1 enzyme.
The combination of E+ the PD-1 inhibitor pembrolizumab (P) is being evaluated in an open-
label, phase 1/2 study in multiple tumor types (ECHO-202/KEYNOTE-037). We report phase
1 and 2 efficacy and safety data for patients (pts) with advanced melanoma (27Feb2017
data cutoff). Methods: Pts previously treated with checkpoint inhibitors were excluded. Pts …
3-dioxygenase 1 (IDO1). Epacadostat (E) is a potent, selective inhibitor of the IDO1 enzyme.
The combination of E+ the PD-1 inhibitor pembrolizumab (P) is being evaluated in an open-
label, phase 1/2 study in multiple tumor types (ECHO-202/KEYNOTE-037). We report phase
1 and 2 efficacy and safety data for patients (pts) with advanced melanoma (27Feb2017
data cutoff). Methods: Pts previously treated with checkpoint inhibitors were excluded. Pts …